Skip to main content

Robert Langer

MIT Institute Professor and biomedical engineering pioneer; co-founder of Moderna and 40+ biotech companies, known as the "Edison of Medicine."

Sep 11, 2026

5:01
What was the landscape of biomaterials when you were pioneering this field in the 1970s? Yeah,
5:07
well, it's interesting.
5:08
Most biomaterials that people used in the body were largely driven by medical doctors, clinicians.
5:15
And what they do is they would often go to their house and find an object that would kind of resemble the organ or tissue they wanted to fix.
5:23
So just to give a few examples, the material in the artificial heart, that was a lady's girdle material because it had a good, you know, good buoyancy or flex life.
5:33
And the material in a breast implant, that was actually, one of them was actually a mattress stuffing because it was the right squishiness.
5:39
The material in a, what's called a vascular graft, an artificial blood vessel, that was a surgeon going to a clothes store and finding something they could sew well with.

10 MINS LATER

15:56
What are some of the hurdles that you've faced entrepreneurially, even outside of the development of your lab in the early days in the 1980s?
DavidHOST
1:52
So the first question is, Bob, can multi-receptor pharmacology and smart delivery be unified? Are they best kept separate?
2:00
Yeah.
2:01
I, I think they can be unified, but I don't think it's straightforward.
2:04
I think it's, you know, I, I think really the idea of, well, in general, a theranostic, you know, a, a, a system that can diagnose things and tell you what to do, I think is a good idea.
2:16
But, you know, I don't think that they're...
2:19
It, it, it's not necessarily that simple.
2:22
I always think it's good to be able to do one thing well first.

6 MINS LATER

DavidHOST
8:41
Yeah
1:52
So the first question is, Bob, can multi-receptor pharmacology and smart delivery be unified? Are they best kept separate?
2:00
Yeah.
2:01
I, I think they can be unified, but I don't think it's straightforward.
2:04
I think it's, you know, I, I think really the idea of, well, in general, a theranostic, you know, a, a, a system that can diagnose things and tell you what to do, I think is a good idea.
2:16
But, you know, I don't think that they're...
2:19
It, it, it's not necessarily that simple.
2:22
I always think it's good to be able to do one thing well first.

7 MINS LATER

9:20
Okay.
16:36
What has been the, what has kept you optimistic during this time, during this pandemic? What has kept you optimistic?
16:42
Well, two things.
16:43
Two, two, two things.
16:44
One of the things that we're, I've been doing is I've been spending a lot of time trying to fight this pandemic.
16:51
You know, one of the companies I helped start is Moderna, and Moderna's been one of the leading companies in terms of creating the COVID vaccine.
16:58
You know, so they're now in what's called phase three trials for doing it.
17:02
And actually, almost every one of the companies that's doing, uh, an RNA vaccine, and those are the leading ones in terms of moving forward in the clinic, uses nanoparticles, uh, you know, which is an area to, to deliver the RNA.

46 MINS LATER

speaker_6NARRATOR
63:39
Here are some of Bob's responses to those questions.
16:37
What has kept you optimistic during this time, during this pandemic? What has kept you optimistic?
16:42
Well, two things.
16:43
Two, two, two things.
16:44
One of the things that we're, I've been doing is I've been spending a lot of time trying to fight this pandemic.
16:51
You know, one of the companies I helped start is Moderna.
16:53
Moderna has been one of the leading companies in terms of creating the COVID vaccine.
16:58
You know, so they're now in what's called phase three trials for doing it.

47 MINS LATER

speaker_6UNKNOWN
63:39
Here are some of Bob's responses to those questions.
9:56
So what would be the downside of being patent focused?
9:59
Well, I actually feel that it's still I mean, how should I say this? The downside that people might say is that if you have patents, then that prevents other people from doing things.
10:13
The problem in the medical area is you won't have to worry about people It just goes back to the example I gave you.
10:22
Unfortunately, you won't get the money.
10:24
I mean, I can't imagine any investors have a choice, right? I'll pick the United States.
10:29
You could invest in the next Facebook or the next Moderna.
10:34
Well, Facebook, you know, it does, has done pretty well.

6 MINS LATER

16:40
What do you think about that?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.